

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

31st January, 2022

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sirs,

Sub: Press Release – ALKEM enters into an exclusive license agreement with Johns Hopkins University.

This is to intimate you that Alkem Laboratories Limited (the “Company”) and Johns Hopkins University, on behalf of its School of Medicine (JHU) have entered into an exclusive license agreement for the development and commercialization of JHU’s novel target and technology that will help patients with colorectal cancer.

A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**


Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

ALKEM enters into an exclusive license agreement with Johns Hopkins University

Mumbai, January 31 2022: We are pleased to announce that Johns Hopkins University, on behalf of its School of Medicine (JHU) and Alkem Laboratories Limited (Alkem), one of India's largest global pharmaceutical companies, have entered into an exclusive license agreement for the development and commercialization of JHU's novel target and technology that will help patients with colorectal cancer. This technology, a novel target, will serve as a bona fide biomarker and antagonist in human colorectal cancer based on angiogenesis and inflammation.

According to Alkem's Managing Director, Mr. Sandeep Singh: "This collaboration is a stepping stone to a long-term symbiotic relationship between JHU and Alkem, to help bring novel therapies to market". Further, Alkem's President & Chief Medical Officer, Dr. Akhilesh Sharma stated: "We aspire that this will be a significant step in fostering continued academic and clinical collaboration between Alkem and JHU for addressing unmet patient needs." He further added that, Alkem will be working with the Director of the Sphingolipid Signaling and Vascular Biology Laboratory at the Johns Hopkins University School of Medicine on this novel target". Alkem acknowledges Mr. Jay Nadkarni's role in the said collaboration.

About Alkem Laboratories Ltd.

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The Company also has presence in more than 40 international markets, with the United States being its key focus market.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

For further information or queries, please contact:

Gagan Borana

Investor Relations

Tel: +91 22 3982 9960 / Mobile: +91 98190 56333

E-mail: gagan.borana@alkem.com